Copeptin: What This Lab Test Actually Measures

The Biology Behind Copeptin

Copeptin is a 39-amino-acid glycopeptide cleaved from the C-terminal end of pre-provasopressin, the same precursor molecule that produces arginine vasopressin (AVP) and neurophysin II. All three peptides are released from the posterior pituitary in equimolar quantities each time the hypothalamus signals water retention or vascular tone adjustment [1].

AVP itself is notoriously hard to measure in clinical practice. It circulates at picomolar concentrations, has a plasma half-life between 10 and 20 minutes, and binds to platelets in vitro, which means that even small delays in sample processing skew results [2]. For decades, this instability forced endocrinologists to rely on indirect provocation tests like the water deprivation test (WDT), which requires 8-16 hours of supervised fluid restriction and carries real risks for patients with polyuria.

Copeptin solved this measurement problem. The peptide is stable in unprocessed blood for at least 7 days at room temperature [1]. It shows no significant platelet binding. A single blood draw processed on a standard automated immunoassay platform (the BRAHMS Copeptin proAVP KRYPTOR by Thermo Fisher) returns results in under an hour. Because copeptin mirrors AVP release on a 1:1 molar basis, every rise or fall in vasopressin secretion shows up as a proportional change in copeptin concentration [3].

The signal copeptin carries is straightforward: it tells you how much vasopressin the posterior pituitary just released. High copeptin means high AVP secretion. Low copeptin means the pituitary is not producing AVP in meaningful quantities.

Normal Copeptin Range and How to Interpret Results

For healthy, well-hydrated adults, baseline copeptin typically falls between 1.0 and 13.8 pmol/L [4]. Men tend to run higher than women, with median values around 5.2 pmol/L versus 3.7 pmol/L in several population-based cohorts [5]. This sex difference likely reflects the influence of estrogen on vasopressin receptor sensitivity and central osmostat thresholds.

Context determines interpretation. A copeptin of 4.9 pmol/L is unremarkable during routine screening but becomes diagnostically significant if drawn after hypertonic saline infusion in a patient with suspected diabetes insipidus. The test's power comes from pairing the number with the clinical scenario.

Several physiologic variables push copeptin upward independent of disease: acute physical stress, surgery, nausea, hypotension, and severe pain all trigger vasopressin release and therefore raise copeptin [6]. Fasting versus fed state has minimal effect on levels, but extreme dehydration will raise values. Laboratories using the BRAHMS KRYPTOR assay report a functional sensitivity of 0.9 pmol/L, which is low enough to distinguish suppressed AVP states from normal baseline secretion [1].

Age modestly increases copeptin. In the Malmö Diet and Cancer Cardiovascular Cohort (N=5,131), copeptin rose approximately 0.3 pmol/L per decade of life after age 45, even after adjustment for renal function and blood pressure [5]. Chronic kidney disease (eGFR <60 mL/min) also raises copeptin due to reduced renal clearance and volume-mediated AVP stimulation.

Diagnosing Diabetes Insipidus: The Copeptin-First Approach

The traditional water deprivation test has been the diagnostic standard for diabetes insipidus (DI) since the 1970s. It works, but it is uncomfortable, time-consuming, and has a diagnostic accuracy of only about 70% for distinguishing partial central DI from primary polydipsia [7]. This limitation drove the search for something better.

In 2018, Fenske and colleagues published a landmark trial in the New England Journal of Medicine (N=156) comparing a copeptin-based protocol against the classical WDT. The study used hypertonic saline-stimulated copeptin measurement: patients received a controlled 3% saline infusion until serum sodium reached 150 mmol/L, at which point copeptin was drawn. A copeptin value <4.9 pmol/L after stimulation identified central DI with 93.2% sensitivity and 100% specificity. The WDT achieved only 76.6% overall diagnostic accuracy in the same cohort [7].

"The copeptin-based approach offers a simpler, more reliable alternative to the water deprivation test for the differential diagnosis of diabetes insipidus," wrote Dr. Mirjam Christ-Crain in her accompanying 2019 Nature Reviews Endocrinology analysis of the evidence [3].

A follow-up multicenter study by Refardt et al. (2020, N=144) validated these findings across five European centers and confirmed that the hypertonic saline-stimulated copeptin cutoff of 4.9 pmol/L correctly classified 96.5% of patients with polyuria-polydipsia syndrome [8]. Based on this evidence, the Endocrine Society's 2023 guidance on arginine vasopressin deficiency (the renamed condition formerly called central diabetes insipidus) now recommends copeptin-based testing as the preferred first-line diagnostic approach [9].

For practical interpretation in the DI workup:

• Stimulated copeptin <4.9 pmol/L: consistent with central DI (AVP deficiency)
• Stimulated copeptin ≥4.9 pmol/L with dilute urine: suggests nephrogenic DI or primary polydipsia
• Baseline (unstimulated) copeptin >21.4 pmol/L: can rule out central DI without any stimulation test at all [8]

The arginine infusion test has also emerged as a gentler alternative to hypertonic saline. In this protocol, arginine hydrochloride is infused over 30 minutes, and copeptin is drawn 60 minutes later. A copeptin cutoff of 3.8 pmol/L after arginine stimulation differentiated central DI from primary polydipsia with 93% accuracy in a 2021 Swiss cohort [10]. This approach avoids the need to induce hypernatremia, making it safer for outpatient settings.

Copeptin in Acute Myocardial Infarction Rule-Out

Beyond endocrinology, copeptin has found a second clinical niche in emergency cardiology. When a patient presents to the emergency department with chest pain, the standard protocol involves serial high-sensitivity cardiac troponin (hs-cTn) measurements drawn at presentation and again at 1-3 hours. This waiting period creates bottlenecks.

Copeptin rises within minutes of acute myocardial stress, peaking before troponin does. A 2009 study by Reichlin et al. (N=487) demonstrated that adding copeptin to a single troponin measurement at ED presentation increased the negative predictive value for AMI to 99.7%, compared with 95.3% for troponin alone [11].

The CHOPIN trial (N=1,967), published in the Journal of the American College of Cardiology in 2013, confirmed these results in a larger multicenter cohort. Patients with both hs-cTnT <14 ng/L and copeptin <10 pmol/L at presentation had a 30-day AMI rate of only 0.1% [12]. This dual-marker strategy could safely discharge low-risk chest pain patients after a single blood draw.

The 2020 European Society of Cardiology guidelines on acute coronary syndromes acknowledge copeptin as a supplementary biomarker that can accelerate rule-out when used alongside high-sensitivity troponin, though they stop short of mandating it [13]. Adoption has been strongest in German and Swiss emergency departments, where the BRAHMS assay is widely available.

What High Copeptin Levels Mean

Elevated copeptin reflects increased vasopressin secretion, and the causes span multiple organ systems. Acute illness is the most common driver. Copeptin rises in sepsis, pneumonia, stroke, and heart failure because each of these conditions activates the hypothalamic-pituitary-adrenal axis and triggers non-osmotic AVP release [6].

Specific conditions associated with high copeptin:

Heart failure. In the BACH trial (N=1,641), copeptin levels above 24 pmol/L at admission predicted 90-day mortality in acute heart failure patients with a hazard ratio of 2.6 (95% CI, 1.8-3.7) independent of BNP and troponin [14]. Copeptin here reflects neurohormonal activation and hemodynamic stress, not water balance pathology.

Sepsis and critical illness. Copeptin measured within 24 hours of ICU admission exceeded 100 pmol/L in many patients with septic shock in the study by Morgenthaler et al. (2007, N=101), and levels above this threshold predicted 28-day mortality with an area under the ROC curve of 0.75 [15].

Syndrome of inappropriate ADH secretion (SIADH). Copeptin is typically elevated in SIADH because the condition is defined by excess vasopressin activity. Values vary widely (often 5-50 pmol/L) depending on the underlying cause. Copeptin does not replace sodium and osmolality measurements for SIADH diagnosis but may help differentiate SIADH from cerebral salt wasting in neurosurgical patients [3].

Chronic kidney disease. Copeptin rises progressively as GFR declines. In the PREVEND cohort (N=4,068), each doubling of copeptin was associated with a 17% increased risk of developing new-onset CKD over 7 years [16].

What Low Copeptin Levels Mean

A suppressed copeptin (generally <2.0 pmol/L under basal conditions or <4.9 pmol/L after osmotic stimulation) indicates that the posterior pituitary is not releasing vasopressin in adequate amounts.

Central diabetes insipidus (now termed AVP deficiency) is the primary clinical cause. In this condition, autoimmune destruction, pituitary surgery, trauma, or infiltrative disease damages the vasopressin-producing neurons of the hypothalamus or posterior pituitary. Copeptin stays low even when the body desperately needs water retention. Patients produce large volumes of dilute urine (often 6-18 liters per day) and experience relentless thirst [9].

Low copeptin can also be seen in primary polydipsia, but with an important distinction: copeptin may be low-normal at baseline because chronic over-hydration suppresses AVP through negative feedback. The stimulated copeptin test separates these two conditions. After hypertonic saline raises serum sodium above 150 mmol/L, patients with primary polydipsia mount a normal copeptin response (≥4.9 pmol/L), while those with central DI cannot [7].

Medications that suppress vasopressin signaling, including ethanol and certain anticonvulsants like phenytoin, may transiently lower copeptin. These effects are generally modest and short-lived.

How to Lower Copeptin

Because copeptin reflects vasopressin release rather than acting as an independent pathologic agent, lowering copeptin means reducing the stimulus that drives AVP secretion.

Adequate hydration is the most direct lever. In healthy volunteers, increasing water intake from 1.5 L/day to 3.0 L/day for one week reduced copeptin by approximately 40% in the Water Intake Trial (N=82) published in the American Journal of Clinical Nutrition [17]. This aligns with basic physiology: when plasma osmolality drops, hypothalamic osmoreceptors signal less AVP release, and copeptin falls proportionally.

In heart failure patients, optimizing volume status with guideline-directed medical therapy (ACE inhibitors, ARBs, SGLT2 inhibitors, mineralocorticoid receptor antagonists) lowers copeptin indirectly by reducing the neurohormonal activation that drives excess vasopressin secretion [14]. Vasopressin receptor antagonists (vaptans) like tolvaptan directly block V2 receptors in the collecting duct; while they do not reduce copeptin itself (copeptin may actually rise as a compensatory response), they counteract the physiologic effect of elevated AVP [3].

For chronic conditions like CKD where copeptin is elevated, the focus should be on treating the underlying disease rather than targeting copeptin specifically. Copeptin in these contexts is a prognostic biomarker, not a treatment target.

How to Raise Copeptin

Clinicians rarely aim to raise copeptin directly. The more common clinical question is whether the pituitary can produce vasopressin at all, and stimulation testing answers this.

The hypertonic saline stimulation test raises copeptin by inducing controlled hypernatremia. Infusing 3% NaCl at 0.05-0.1 mL/kg/min until serum sodium reaches 150 mmol/L triggers a strong copeptin response in anyone with intact posterior pituitary function [7]. This is a diagnostic procedure, not a therapeutic one.

The arginine infusion test achieves a similar result through a different mechanism. Arginine stimulates vasopressin release via a non-osmotic pathway, producing copeptin elevations within 60 minutes [10].

Physiologically, copeptin rises with dehydration, exercise, physical stress, and nausea. A 2016 study in the Journal of Clinical Endocrinology and Metabolism showed that 30 minutes of moderate-intensity cycling increased copeptin by a mean of 8.4 pmol/L above baseline in healthy adults (N=20) [18]. These responses confirm normal pituitary reserve and do not require clinical intervention.

In patients with confirmed central DI, exogenous desmopressin (DDAVP) replaces the missing vasopressin effect but does not raise endogenous copeptin, since the pituitary damage is the root cause. Copeptin measurement before and after treatment helps clinicians calibrate the degree of AVP deficiency and determine appropriate desmopressin dosing [9].

Copeptin vs. Direct AVP Measurement

Direct plasma AVP assays still exist but have largely been supplanted by copeptin for clinical decision-making. The comparison is not close.

"Copeptin measurement has essentially replaced direct vasopressin assays in clinical practice because of its superior pre-analytical stability and diagnostic performance," noted the Endocrine Society in its 2023 clinical practice recommendations for AVP deficiency and excess [9].

Direct AVP requires immediate sample processing on ice, centrifugation within 15 minutes, and extraction before immunoassay. Even under ideal laboratory conditions, the coefficient of variation for AVP assays exceeds 20% [2]. Copeptin's coefficient of variation on the BRAHMS KRYPTOR platform is under 10%, and samples can sit at room temperature for days without significant degradation [1].

The one scenario where direct AVP measurement still has a role is research settings studying rapid vasopressin pulsatility (secretion bursts occurring over seconds to minutes), where copeptin's slightly longer half-life (approximately 26 minutes versus 10-20 minutes for AVP) may smooth out very fast oscillations [3]. For every clinical diagnostic question, copeptin is the preferred analyte.

Practical Considerations for Ordering Copeptin

Not all laboratories offer copeptin testing. In the United States, availability has expanded since 2017 but remains concentrated at academic medical centers and reference laboratories. Quest Diagnostics and Mayo Clinic Laboratories both offer the BRAHMS Copeptin proAVP assay as a send-out test.

No special patient preparation is required. Fasting is not necessary. The sample can be drawn at any time of day, though morning draws in a seated position provide the most standardized baseline. EDTA plasma is the preferred specimen, though serum is acceptable [1].

Insurance coverage varies. Medicare and most commercial payers cover copeptin when ordered for suspected diabetes insipidus with appropriate ICD-10 coding (E23.2 for diabetes insipidus). Coverage for AMI rule-out applications is less consistent, as many US emergency departments have not yet incorporated copeptin into their chest pain protocols.

Copeptin results should always be interpreted alongside serum sodium, plasma osmolality, and urine osmolality. The number alone, without these companion values, can mislead. A copeptin of 3.0 pmol/L means something very different in a eunatremic patient than in someone whose serum sodium is 152 mmol/L.